{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:37:51Z","timestamp":1789918671569,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.10.020","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:00:08Z","timestamp":1761008408000},"page":"298.e1-298.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modifying Post-Transplant Cyclophosphamide Platform to Improve Safety in HLA-Matched Allogeneic HCT: A Reduced Dose Plus Adjunctive Strategies"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-6633","authenticated-orcid":false,"given":"Filipe R.","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Queralt","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Pedraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-9643","authenticated-orcid":false,"given":"Paola","family":"Charry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"de Moner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5934-7912","authenticated-orcid":false,"given":"Julia","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3060-4577","authenticated-orcid":false,"given":"Esther","family":"Carcelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8475-0643","authenticated-orcid":false,"given":"Laia","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Cascos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-0052","authenticated-orcid":false,"given":"Maribel","family":"D\u00edaz-Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-7306","authenticated-orcid":false,"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2025.10.020_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2025.10.020_bib0002","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.020_bib0003","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.020_bib0004","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.020_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.01.009","article-title":"Impact of post-transplantation cyclophosphamide on transfusion requirements in hla-matched sibling peripheral blood stem cell transplantation","volume":"29","author":"Marco-Ayala","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.020_bib0006","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41409-024-02474-1","article-title":"Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis","volume":"60","author":"Meyer","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.020_bib0007","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dulery","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.020_bib0008","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","article-title":"Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study","volume":"98","author":"Soltermann","year":"2019","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.020_bib0009","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.020_bib0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.020_bib0011","doi-asserted-by":"crossref","first-page":"473 e1- e6","DOI":"10.1016\/j.jtct.2023.04.008","article-title":"Successful outcome in patients with myelofibrosis undergoing allogeneic donor hematopoietic cell transplantation using reduced doses of post-transplantation cyclophosphamide: challenges and review of the literature","volume":"29","author":"Garcia-Cadenas","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.020_bib0012","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41409-021-01358-y","article-title":"Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation","volume":"56","author":"Sun","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.020_bib0013","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dulery","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.11.020","article-title":"Post-transplantation cyclophosphamide and tacrolimus for graft-versus-host disease prevention after allogeneic hematopoietic cell transplantation from HLA-matched donors has more advantages than limitations","volume":"30","author":"Salas","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.020_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142567","article-title":"Reduced dose of post-transplant cyclophosphamide with tacrolimus for the prevention of graft-versus-host disease in HLA-matched donor peripheral blood stem cell transplants: a prospective pilot study","volume":"16","author":"Juarez","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.020_bib0016","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/s41409-024-02388-y","article-title":"Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation","volume":"59","author":"Escribano-Serrat","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.020_bib0017","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-023-05542-6","article-title":"Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study","volume":"103","author":"Brusosa","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.020_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.005","article-title":"Effect of CD34(+) cell dose on the outcomes of allogeneic stem cell transplantation with post-transplantation cyclophosphamide","volume":"29","author":"Pedraza","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.020_bib0019","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.020_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.020_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/tid.12175","article-title":"Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations","volume":"16","author":"Blennow","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.020_bib0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease","volume":"52","author":"Garcia-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2025.10.020_bib0023","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.020_bib0024","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.15515","article-title":"Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis","volume":"19","author":"Gimenez","year":"2019","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.020_bib0025","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41409-024-02270-x","article-title":"EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation","volume":"59","author":"Tolosa-Ridao","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.020_bib0026","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41375-024-02445-x","article-title":"Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia","volume":"39","author":"Shimoni","year":"2025","journal-title":"Leukemia"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:30:12Z","timestamp":1775100612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666636725015234"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modifying Post-Transplant Cyclophosphamide Platform to Improve Safety in HLA-Matched Allogeneic HCT: A Reduced Dose Plus Adjunctive Strategies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}